Dr Catherine Toong

Malik S; Toong C, 2023, 'Monoclonal antibody interference in electrophoresis', Pathology, vol. 55, pp. 163 - 165, http://dx.doi.org/10.1016/j.pathol.2022.05.014

Srinivasan A; De Cruz P; Sam M; Toong C; van Langenberg DR, 2023, 'Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses', Journal of Gastroenterology and Hepatology (Australia), http://dx.doi.org/10.1111/jgh.16133

Liu Z; Julsgaard M; Zhu X; Martin J; Barclay ML; Cranswick N; Gibson PR; Gearry RB; van der Giessen J; Connor SJ; Rosella O; Grosen A; Toong C; Flanagan E; Wieringa JW; Janneke van der Woude C; Bell SJ, 2022, 'Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children', Journal of Crohn's & colitis, vol. 16, pp. 1835 - 1844, http://dx.doi.org/10.1093/ecco-jcc/jjac093

Stoyanov A; Toong C; Kong Y; Chen R; Urriola N, 2022, 'Serum protein electrophoresis and rheumatoid factor analysis is an effective screening strategy for cryoglobulinaemia', Pathology, http://dx.doi.org/10.1016/j.pathol.2022.09.004

Gu B; De Gregorio M; Pipicella JL; Vande Casteele N; Andrews JM; Begun J; Connell W; D'Souza B; Gholamrezaei A; Hart A; Liew D; Radford-Smith G; Rimola J; Sutherland T; Toong C; Woods R; Wu Y; Xuan W; Williams AJ; Ng W; Ding NS; Connor S, 2021, 'Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol', BMJ open, vol. 11, http://dx.doi.org/10.1136/bmjopen-2020-043921

West TA; Sam M; Toong C, 2021, 'Comparison of three commercially available ELISA assays for anti-infliximab antibodies', Pathology, vol. 53, pp. 508 - 514, http://dx.doi.org/10.1016/j.pathol.2020.08.020

Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S, 2021, 'Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings', Internal Medicine Journal, vol. 51, pp. 739 - 745, http://dx.doi.org/10.1111/imj.14644

Yap JY; Moens L; Lin MW; Kane A; Kelleher A; Toong C; Wu KHC; Sewell WA; Phan TG; Hollway GE; Enthoven K; Gray PE; Casas-Martin J; Wouters C; De Somer L; Hershfield M; Bucciol G; Delafontaine S; Ma CS; Tangye SG; Meyts I, 2021, 'Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency', Journal of Clinical Immunology, vol. 41, pp. 1915 - 1935, http://dx.doi.org/10.1007/s10875-021-01141-0

Grey A; Sam M; Lehmann P; Tannous A; Papathomas E; Makris A; Natfaji A; Wong J; Toong C, 2020, 'Estimating urinary losses of rituximab in membranous nephropathy with nephrotic range proteinuria', Pathology, vol. 52, pp. S41 - S41, http://dx.doi.org/10.1016/j.pathol.2020.01.149

Sam MJ; Connor SJ; Ng WWS; Toong CML, 2020, 'Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies', Therapeutic Drug Monitoring, vol. 42, pp. 821 - 828, http://dx.doi.org/10.1097/FTD.0000000000000795

Malik S; Toong C, 2019, 'Monoclonal antibody interference in serum electrophoresis', Pathology, vol. 51, pp. S67 - S67, http://dx.doi.org/10.1016/j.pathol.2018.12.156

West T; Sam M; Toong C, 2019, 'Comparison of three commercially-available elisa assays for anti-infliximab antibodies', Pathology, vol. 51, pp. S132 - S133, http://dx.doi.org/10.1016/j.pathol.2018.12.383

van der Poorten DK; McLeod D; Ahlenstiel G; Read S; Kwok A; Santhakumar C; Bassan M; Culican S; Campbell D; Wong SWJ; Evans L; Jideh B; Kane A; Katelaris CH; Keat K; Ko Y; Lee JA; Limaye S; Lin MW; Murad A; Rafferty M; Suan D; Swaminathan S; Riminton SD; Toong C; Berglund LJ, 2018, 'Gastric Cancer Screening in Common Variable Immunodeficiency', Journal of Clinical Immunology, vol. 38, pp. 768 - 777, http://dx.doi.org/10.1007/s10875-018-0546-3

Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW, 2017, 'Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases', Alimentary Pharmacology and Therapeutics, vol. 46, pp. 1037 - 1053, http://dx.doi.org/10.1111/apt.14368

Toong CML; Lee MWM; Connor S; Ng W, 2017, 'Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits: author reply', Pathology, vol. 49, pp. 334 - 335, http://dx.doi.org/10.1016/j.pathol.2017.01.005

Lee MWM; Connor S; Ng W; Toong CML, 2016, 'Comparison of infliximab drug measurement across three commercially available ELISA kits', Pathology, vol. 48, pp. 608 - 612, http://dx.doi.org/10.1016/j.pathol.2016.07.001

Malkan A; Cappelen-Smith C; Beran R; Griffith N; Toong C; Wang MX; Cordato D, 2015, 'Anti-synthetase syndrome associated with anti PL-12 and anti-Signal recognition particle antibodies and a necrotizing auto-immune myositis', Journal of Clinical Neuroscience, vol. 22, pp. 396 - 398, http://dx.doi.org/10.1016/j.jocn.2014.04.031

Malkan A; Cordato D; Griffith N; Cappelen-Smith C; Toong C; Beran R, 2014, '10. Anti-synthetase syndrome associated with necrotizing myositis – Utility of myositis specific autoantibodies in predicting prognosis and choice of treatment', Clinical Neurophysiology, vol. 125, pp. e4 - e4, http://dx.doi.org/10.1016/j.clinph.2013.10.032

Barker R; Lehmann P; O’Neill S; Toong C, 2012, 'Phar lap and the filly: validating the anti-DSDNA-NCX IgG ELISA', Pathology, vol. 44, pp. S69 - S69, http://dx.doi.org/10.1016/s0031-3025(16)32777-5

Toong C, 2012, 'Use of cardiac MR imaging to evaluate the presence of myocarditis in autoimmune myositis: three cases', Rheumatology International, vol. 32, pp. 779 - 782, http://dx.doi.org/10.1007/s00296-009-1324-6

Toong C; Adelstein S; Phan TG, 2011, 'Clearing the complexity: immune complexes and their treatment in lupus nephritis', International Journal of Nephrology and Renovascular Disease, vol. 4, pp. 17 - 28, http://dx.doi.org/10.2147/IJNRD.S10233

Toong C; Puranik R; Adelstein S, 2009, 'Use of Cardiac MR Imaging to Evaluate the Presence of Myocarditis in Autoimmune Myositis: 3 Cases', Heart, Lung and Circulation, vol. 18, pp. S59 - S59, http://dx.doi.org/10.1016/j.hlc.2009.05.130

Toong C; Quin J, 2007, 'Investigation of the patient with suspected allergy', Medicine Today, vol. 8, pp. 49 - 56

Hu H; Carr A; Deenick E; Phan TT; Kelleher A; Tong W; Moore J; Evans L; Toong C; Murad A; Kane A, 2022, 'PATIENT PERCEPTIONS OF HEALTH-RELATED QUALITY OF LIFE IN AN AUSTRALIAN ADULT PRIMARY IMMUNODEFICIENCY COHORT', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 52, pp. 27 - 27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862654200072&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Srinivasan A; Cruz PD; Sam M; Toong C; Langenberg DRV, 2022, 'Mo1541: INFLIXIMAB DOSE INTENSIFICATION FOR SECONDARY LOSS OF RESPONSE IN IBD: UPFRONT INTENSIFICATION IS SIMILARLY EFFECTIVE TO DOSE INTERVAL SHORTENING WITH THE ADDED BENEFIT OF EARLY PREDICTORS OF RESPONSE', in Gastroenterology, Elsevier BV, Vol. 162, pp. S - 810, http://dx.doi.org/10.1016/s0016-5085(22)61913-9

Srinivasan A; De Cruz P; Sam M; Toong C; Van Langenberg D, 2022, 'Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, Vol. 16, pp. I437 - I438, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778573401167&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Srinivasan A; De Cruz P; Sam M; Toong C; Van Langenberg DR, 2022, 'INFLIXIMAB DOSE INTENSIFICATION FOR SECONDARY LOSS OF RESPONSE IN IBD: UPFRONT INTENSIFICATION IS SIMILARLY EFFECTIVE TO DOSE INTERVAL SHORTENING WITH THE ADDED BENEFIT OF EARLY PREDICTORS OF RESPONSE', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, CA, San Diego, Vol. 162, pp. S810 - S810, presented at Digestive Disease Week (DDW), CA, San Diego, 21 May 2022 - 24 May 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826446203163&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Srinivasan A; De Cruz P; Sam M; Toong C; van Langenberg D, 2022, 'P462 Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in Journal of Crohn's and Colitis, Oxford University Press (OUP), Vol. 16, pp. i437 - i438, http://dx.doi.org/10.1093/ecco-jcc/jjab232.589

Srinivasan A; De Cruz P; Sam M; Toong C; van Langenberg D, 2022, 'Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, Vol. 16, pp. I437 - I438, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778573400589&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Stoyanov A; Toong C; Kong Y; Urriola N, 2022, 'Serum protein electrophoresis and rheumatoid factor analysis as a screening strategy for cryoglobulinaemia', in Pathology, Elsevier BV, Vol. 54, pp. S82 - S82, http://dx.doi.org/10.1016/j.pathol.2021.12.267

Tong W; Loprete J; Richardson R; Kane A; Katelaris C; Post J; Wainstein B; Wong M; Campbell D; Swaminathan S; Suan D; Evans L; Law M; McMullan B; Murad A; Toong C; Torda A; Carr A, 2021, 'STANDARDISED TESTING AND COMMUNICATION INCREASE BETA-LACTAM ALLERGY DELABELLING EFFECTIVENESS: RESULTS OF 'DE-LABELLING PATIENTS WITH ANTIBIOTIC ALLERGY IN SYDNEY ADULT AND PAEDIATRIC HOSPITALS'', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 51, pp. 13 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713717300029&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Loprete J; Richardson R; Kane A; Katelaris C; Post J; Wainstein B; Wong M; Campbell D; Evans L; Mcmullan B; Murad A; Toong C; Torda A; Carr A, 2020, 'De-labelling patients with antibiotic allergy in Sydney adult and paediatric hospitals-towards standardisation and improved patient outcomes', in ALLERGY, WILEY, ENGLAND, London, Vol. 75, pp. 216 - 216, presented at European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), ENGLAND, London, 06 June 2020 - 08 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000566847300395&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Loprete J; Richardson R; Kane A; Katelaris C; Post J; Wainstein B; Wong M; Campbell D; Evans L; McMullan B; Murad A; Toong C; Torda A; Carr A; Tong W, 2019, 'DE-LABELLING PATIENTS WITH ANTIBIOTIC ALLERGY IN SYDNEY ADULT AND PAEDIATRIC HOSPITALS- TOWARDS STANDARDISATION AND IMPROVED PATIENT OUTCOMES', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 49, pp. 15 - 15, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488891400038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Berglund LJ; McLeod D; Ahlenstiel G; Read S; Kwok A; Santhikumar C; Bassan M; Evans L; Kane A; Katelaris CH; Keat K; Ko Y; Lee JA; Limaye S; Lin MW; Murad A; Rafferty M; Suan D; Swaminathan S; Riminton DS; Toong C; van der Poorten DK, 2018, 'GASTRIC CANCER SCREENING IN COMMON VARIABLE IMMUNODEFICIENCY', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 48, pp. 27 - 27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449673000073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lin B; Wu Y; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Ng W; Connor S, 2017, 'Biological level testing in inflammatory bowel disease identifies inappropriate use of infliximab, with substantial associated cost savings', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 132 - 133, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100240&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mitrev N; Vande Casteele N; Seow C; Andrews JM; Connor SJ; Moore G; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; Van Langenberg D; Ward MG; Leong RW, 2017, 'Therapeutic drug monitoring-guided biological drug therapy in inflammatory bowel disease: Consensus statements of the Australian Inflammatory Bowel Disease Association (AIBDA) and Gastroenterological Society of Australia (GESA)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 136 - 138, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100247&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Ng W; Connor S, 2017, 'Secondary loss of response is the most common indication for infliximab level testing in inflammatory bowel disease: The Australian experience', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 153 - 154, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100273&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Barker R; Toong C, 2013, 'AN AETIOLOGY FOR IgG4 RELATED DISEASE?', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 22 - 22, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000323685200066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Urriola N; Toong C, 2013, 'A BRAF NEW WORLD', Vol. 43, pp. 25 - 25, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000323685200079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1